Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cells, characterized by skin lesions and frequent involvement of bone marrow and lymphoid tissues. Patients have a poor prognosis, making early diagnosis and advanced treatments, including targeted therapies, crucial for improving outcomes.

In this podcast, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, and Emanuele Angelucci, MD, Armando Businco Oncology Hospital, Sardegna, Italy, discuss the treatment and monitoring of BPDCN. They highlight the role of CD123-targeting agents, including tagraxofusp, the involvement of the central nervous system (CNS), and share strategies for treating adolescents and young adults (AYAs) with this aggressive disease.

The post BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients appeared first on VJHemOnc.